Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2B | P18089 | 2/20 | 0.69 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.69 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.69 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.69 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.69 |
| ▸ | HTR2A | P28223 | 1/20 | 0.69 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.69 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.69 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.47 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30474512 | 0.82 | ADRA2B (0.50) | ADRA2BADRA2CADRA1AOPRK1SLC6A2 | |
| SCHEMBL15003030 | 0.82 | ADRA2B (0.71) | ADRA2BADRA2CADRA1AOPRK1SLC6A2 | |
| SCHEMBL1834931 | 0.82 | TSHR (0.51) | ADRA2BADRA2CADRA1AOPRK1SLC6A2 | |
| Benzphetamine SCHEMBL678807 | 0.82 | ADRA2B (1.00) | ADRA2BADRA2CADRA1AOPRK1SLC6A2 | |
| Benzphetamine SCHEMBL49120 | 0.82 | ADRA2B (1.00) | ADRA2BADRA2CADRA1AOPRK1SLC6A2 | |
| Benzphetamine SCHEMBL19285634 | 0.82 | ADRA2B (1.00) | ADRA2BADRA2CADRA1AOPRK1SLC6A2 | |
| SCHEMBL10773369 | 0.82 | ADRA2B (0.50) | ADRA2BADRA2CADRA1AOPRK1SLC6A2 | |
| SCHEMBL6054336 | 0.82 | TSHR (0.51) | ADRA2BADRA2CADRA1AOPRK1SLC6A2 | |
| SCHEMBL1834929 | 0.82 | TSHR (0.51) | ADRA2BADRA2CADRA1AOPRK1SLC6A2 | |
| SCHEMBL17559714 | 0.81 | ADRA2B (0.55) | ADRA2BADRA2CADRA1AOPRK1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260085060-A1 | THERAPEUTIC COMPOUNDS | INDIVIOR UK LTD (GB) | 2026-03-26 | — | — | US | disclosed |
| US-11753398-B2 | Therapeutic compounds | C4X DISCOVERY LIMITED (GB) | 2023-09-12 | — | — | US | disclosed |
| US-11753398-B2 | Therapeutic compounds | C4X DISCOVERY LIMITED (GB) | 2023-09-12 | — | — | US | disclosed |
| US-11753398-B2 | Therapeutic compounds | C4X DISCOVERY LIMITED (GB) | 2023-09-12 | — | — | US | disclosed |
| US-20210395227-A1 | THERAPEUTIC COMPOUNDS | INDIVIOR UK LIMITED (GB) | 2021-12-23 | — | — | US | disclosed |
| US-20210395227-A1 | THERAPEUTIC COMPOUNDS | INDIVIOR UK LIMITED (GB) | 2021-12-23 | — | — | US | disclosed |
| US-11130746-B2 | Therapeutic compounds | C4X DISCOVERY LIMITED (GB) | 2021-09-28 | — | — | US | disclosed |
| US-20200255404-A1 | THERAPEUTIC COMPOUNDS | INDIVIOR UK LIMITED (GB) | 2020-08-13 | — | — | US | disclosed |
| US-10696654-B2 | Therapeutic compounds | C4X DISCOVERY LIMITED (GB) | 2020-06-30 | — | — | US | disclosed |
| US-10696654-B2 | Therapeutic compounds | C4X DISCOVERY LIMITED (GB) | 2020-06-30 | — | — | US | disclosed |
| EP-3408265-B1 | THERAPEUTIC COMPOUNDS | C4X DISCOVERY LTD (GB) | 2020-05-13 | — | — | EP | disclosed |
| EP-3408265-B1 | THERAPEUTIC COMPOUNDS | C4X DISCOVERY LTD (GB) | 2020-05-13 | — | — | EP | disclosed |
| US-20190040041-A1 | THERAPEUTIC COMPOUNDS | INDIVIOR UK LIMITED (GB) | 2019-02-07 | — | — | US | disclosed |
| US-20190040041-A1 | THERAPEUTIC COMPOUNDS | INDIVIOR UK LIMITED (GB) | 2019-02-07 | — | — | US | disclosed |
| WO-2017158151-A1 | PYRIMIDONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | SAVIRA PHARMACEUTICALS GMBH (AT) | 2017-09-21 | — | — | WO | disclosed |
| WO-2017129829-A1 | THERAPEUTIC COMPOUNDS | C4X DISCOVERY LIMITED (GB) | 2017-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10696654-B2 | Therapeutic compounds | HCRTR2, HCRTR1, NPY1R | ADRA2B 200/4885ADRA2C 148/4885ADRA1A 158/4885 |
| US-11753398-B2 | Therapeutic compounds | HCRTR2, HCRTR1, NPY1R | ADRA2B 200/4885ADRA2C 148/4885ADRA1A 158/4885 |
| US-20190040041-A1 | THERAPEUTIC COMPOUNDS | HCRTR2, HCRTR1, NPY1R | ADRA2B 200/4885ADRA2C 148/4885ADRA1A 158/4885 |
| US-11130746-B2 | Therapeutic compounds | HCRTR2, HCRTR1, NPY1R | ADRA2B 200/4885ADRA2C 148/4885ADRA1A 158/4885 |
| US-20200255404-A1 | THERAPEUTIC COMPOUNDS | HCRTR2, HCRTR1, NPY1R | ADRA2B 200/4885ADRA2C 148/4885ADRA1A 158/4885 |
| US-20210395227-A1 | THERAPEUTIC COMPOUNDS | HCRTR2, HCRTR1, NPY1R | ADRA2B 200/4885ADRA2C 148/4885ADRA1A 158/4885 |
| US-20260085060-A1 | THERAPEUTIC COMPOUNDS | HCRTR2, HCRTR1, NPY1R | ADRA2B 501/4885ADRA2C 1520/4885ADRA1A 1600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.